Published: Monday, June 16, 2025 · 1:45 AM | Updated: Monday, June 16, 2025 · 1:45 AM
📊 366 views

Innovent Biologics (IVBXF, Financial) has commenced the GLORY-OSA Phase 3 clinical trial, dosing its first participant. The trial focuses on mazdutide, a dual receptor agonist targeting glucagon and glucagon-like peptide-1, in Chinese patients suffering from moderate-to-severe obstructive sleep apnea and obesity. This marks the seventh Phase 3 study for mazdutide in China, emphasizing its potential role in treating obesity and related metabolic disorders. The goal is to acquire robust evidence to support clinical applications of this treatment.
MORE IN INSIDE INVESTMENT NEWS
Cisco AI Revenue Soars: Bullish Outlook for Networking Giant
Published: Friday, November 13, 2026 · 9:39 AM
Nebius Shares Plunge 10%: A Warning on Cloud Capex & Outlook
Published: Thursday, November 12, 2026 · 8:27 AM
